US Drug Recall Register

FDA Drug Recalls

2,661 recalls, newest first

Class II · Moderate risk Ongoing

Metoprolol Succinate Extended-Release Tablets

Reason Failed Dissolution Specifications: Product failed to meet dissolution acceptance criteria in the stability studies at the 6th month (25¿C/60% RH) long-term.

Granules Pharmaceuticals Inc. NDC 70010-780-01 D-0510-2025
Class II · Moderate risk Ongoing

Lisinopril and Hydrochlorothiazide Tablets USP 20mg/12.5mg

Reason Product Mix Up: This product is being recalled because of a complaint received that a sealed bottle of lisinopril and hydrochlorothiazide tablets 20mg/12.5 mg had a foreign tablet identified as atazanavir and ritonavir tablet 300mg/100mg.

Lupin Pharmaceuticals Inc. NDC 68180-519-01 D-0532-2025
Class II · Moderate risk Ongoing

Levothyroxine Sodium Tablets

Reason Subpotent Drug: Assay below the approved specification

Accord Healthcare, INC. NDC 16729-456-17 D-0524-2025
Class II · Moderate risk Ongoing

Levothyroxine Sodium Tablets

Reason Subpotent Drug: Assay below the approved specification

Accord Healthcare, INC. NDC 16729-455-17 D-0523-2025
Class II · Moderate risk Ongoing

Levothyroxine Sodium Tablets

Reason Subpotent Drug: Assay below the approved specification

Accord Healthcare, INC. NDC 16729-452-17 D-0522-2025
Class II · Moderate risk Ongoing

Levothyroxine Sodium Tablets

Reason Subpotent Drug: Assay below the approved specification

Accord Healthcare, INC. NDC 16729-451-17 D-0521-2025
Class II · Moderate risk Ongoing

Levothyroxine Sodium Tablets

Reason Subpotent Drug: Assay below the approved specification

Accord Healthcare, INC. NDC 16729-448-15 D-0520-2025
Class II · Moderate risk Ongoing

Levothyroxine Sodium Tablets

Reason Subpotent Drug: Assay below the approved specification

Accord Healthcare, INC. NDC 16729-447-17 D-0519-2025
Class II · Moderate risk Ongoing

Levothyroxine Sodium Tablets

Reason Subpotent Drug: Assay below the approved specification

Accord Healthcare, INC. NDC 16729-447-15 D-0518-2025
Class II · Moderate risk Ongoing

Gabapentin Capsules

Reason Defective container; blister packaging inadequately sealed.

The Harvard Drug Group LLC NDC 55154-3363-0 D-0508-2025
Class II · Moderate risk Ongoing

Gabapentin Capsules

Reason Defective container; blister packaging inadequately sealed.

The Harvard Drug Group LLC NDC 0904-6665-61 D-0507-2025
Class II · Moderate risk Ongoing

Lisdexamfetamine Dimesylate Capsules

Reason Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 9 month long term stability station (25¿C, 60%RH).

Sun Pharmaceutical Industries INC NDC 57664-051-88 D-0516-2025
Class II · Moderate risk Ongoing

0.9% Sodium Chloride Injection USP

Reason Lack of assurance of sterility: pinholes, within the finger boxes used during Form Fill Seal process resulting in leaks.

B Braun Medical INC NDC 0264-7800-10 D-0491-2025
Class III · Low risk Ongoing

Pitavastatin Tablets

Reason Failed Impurities/Degradation Specifications.

Orient Pharma Co., Ltd. Yunlin Plant NDC 0480-3631-98 D-0527-2025
Class III · Low risk Ongoing

Pitavastatin Tablets

Reason Failed Impurities/Degradation Specifications.

Orient Pharma Co., Ltd. Yunlin Plant NDC 0480-3632-98 D-0526-2025
Class III · Low risk Ongoing

Famciclovir Tablets

Reason Presence of Foreign Substance- Black hair strand found attached to a tablet in a sealed bottle.

Macleods Pharmaceuticals Ltd NDC 33342-026-07 D-0509-2025
Class II · Moderate risk Ongoing

Kimmtrak

Reason Subpotent Drug

Immunocore, LLC NDC 80446-0401-01 D-0614-2025
Class I · High risk Ongoing

Orajel Baby

Reason Microbial Contamination of Non-Sterile Products: Fungal contamination of infant oral swabs.

Church & Dwight Inc D-0506-2025
Class I · High risk Ongoing

Zicam Nasal Allclear

Reason Microbial Contamination of Non-Sterile Products: Fungal contamination of nasal swabs.

Church & Dwight Inc D-0505-2025
Class I · High risk Ongoing

Zicam Cold Remedy Medicated Nasal Swabs

Reason Microbial Contamination of Non-Sterile Products: Fungal contamination of nasal swabs.

Church & Dwight Inc D-0504-2025
Class II · Moderate risk Ongoing

LIDOcaine HCL Sterile Injection

Reason Lack of Assurance of Sterility: A recent FDA inspection revealed concerns with the sterile manufacturing process.

Tailstorm Health INC NDC 81483-0001-0 D-0503-2025
Class II · Moderate risk Ongoing

LIDOcaine HCL Sterile Injection

Reason Lack of Assurance of Sterility: A recent FDA inspection revealed concerns with the sterile manufacturing process.

Tailstorm Health INC NDC 81483-0037-0 D-0502-2025
Class II · Moderate risk Ongoing

KETAmine Hydrochloride Injection

Reason Lack of Assurance of Sterility: A recent FDA inspection revealed concerns with the sterile manufacturing process.

Tailstorm Health INC NDC 81483-0007-2 D-0501-2025
Class II · Moderate risk Ongoing

KETAmine Hydrochloride Injection

Reason Lack of Assurance of Sterility: A recent FDA inspection revealed concerns with the sterile manufacturing process.

Tailstorm Health INC NDC 81483-0006-0 D-0500-2025